{
  "id": 5298256,
  "title": "GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront",
  "url": "https://urgent.news/2026/09/03/gsk-to-license-hutchmeds-kras-egfr-cancer-drug-for-110m-upfront",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T09:59:27.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/gsk-to-license-hutchmeds-kras-egfr-cancer-drug-for-110m-upfront/"
  },
  "original_language": "en",
  "account": null,
  "summary": "GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on the line. The Chinese biopharma said ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "HUTCHMED jumps 15% after licensing cancer therapy to GSK for up to $1.295B",
        "url": "https://urgent.news/2026/09/03/hutchmed-jumps-15-after-licensing-cancer-therapy-to-gsk-for-up-to-1",
        "published": "2026-09-03T08:53:58.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}